Canakinumab
- Generic Name
- Canakinumab
- Brand Names
- Ilaris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914613-48-2
- Unique Ingredient Identifier
- 37CQ2C7X93
- Background
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...
- Indication
Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients ≥4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...
- Associated Conditions
- Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF ), Gout Flares, Mevalonate Kinase Deficiency, Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Tumour necrosis factor receptor-associated periodic syndrome
- Associated Therapies
- -
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01302860
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Canakinumab for Pyoderma Gangrenosum
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 5
- Registration Number
- NCT01302795
- Locations
- 🇨🇭
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Efficacy and Safety of Canakinumab in Schnitzler Syndrome
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01276522
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
- Conditions
- Interventions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01242813
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 10
- Registration Number
- NCT01170936
- Locations
- 🇩🇪
Charité-Universitätsmedizin Berlin, Berlin, Germany
Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01148797
- Locations
- 🇮🇱
Meir Medical Center Kfar Saba, Kfar Saba, Israel
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT01088880
- Locations
- 🇹🇷
Istanbul Medical Faculty, Dept of Rheumatology, Capa, Istanbul, Turkey
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
- Conditions
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00995930
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT00991146
- Locations
- 🇯🇵
Novartis Investigative Site, Kyoto-city, Kyoto, Japan
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 341
- Registration Number
- NCT00927810
- Locations
- 🇬🇧
Novartis Investigative site, Jarrow, Tyne & Wear, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.